Chronic lymphocytic leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BTK 26
• CD19 33
• BCL-2 10
• TP53 3
• CD20 10
• CD22 6
• ABL1 2
• PI3K 1
• NOTCH1 0
• CXCR4 0
• STAT3 0
• CD123 1
• CD38 1
• HMGB1 0
• PD-1 0
• PD-L1 0
• EGFR 0
• HDAC 0
• MDM2 0
• PPAR 0
• TIM-3 0
• AKT 0
• ALK 0
• ATM 0
• BCMA 1
• BDNF 0
• BRAF 0
• BRD4 0
• CD30 0
• CD47 0
• CSF1R 1
• CTNNB1 0
• ERK 0
• FAK 0
• FLT3 0
• IDH 0
• IL-23 0
• IL-4 0
• KMT2A 0
• MAPK 0
• MMP-9 0
• NLRP3 0
• NRAS 0
• PCSK9 0
• PRMT5 0
• TLR4 0
• VEGF 0

24 of 45+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, United States· US$390,447 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Rationally directed therapy for CLL

  University of Tx Md Anderson Can Ctr· Houston, United States· US$690,011 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Integrating AI and Deep Mutational Scanning to Predict the Cancer-Promoting Effect of Shelterin Mutations

  University of California Berkeley· Berkeley, United States· US$2,197,943 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · R41

  Development of MCL 1-Targeting Antibody–Drug Conjugates for Cancer Therapy

  Immunogenic Cancer Engineering Therapeutics Llc· Englewood Cliffs, United States· US$412,351 awarded in fiscal year 2026· until Aug 2027

• NIH NEI · R01

  Discovery of novel trifunctional hybrid compounds (TFHCs): potential glaucoma therapy with superior IOP reduction and neuroprotection

  Creighton University· Omaha, United States· US$576,730 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Signaling and Powering Anti-cancer Responses in T Cells SPARC

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €2,500,000· until Oct 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Immuno-Modulatory Platform for Advanced CLL Therapy (IMPACT)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €150,000· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias (LeukemiaBlock)

  Masarykova univerzita· Brno, Czechia· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A single-cell-based solution for an early diagnosis of Richter transformation in patients with chronic lymphocytic leukemia (earlyRTdx)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €150,000· until Oct 2027

10 of 143 running projects, newest first. Listed amounts together: US$97.4m + €16.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

  NCT05094206· Medical College of Wisconsin· Updated 19 Sept 2024

  “Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.”Registry text, quoted unchanged. Source

• Terminated

  Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

  NCT05360238· Mustang Bio· Updated 22 Jul 2024

  “Business reasons”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· BeOne Medicines· Source

• Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

  NCT05797233· National Cancer Institute (NCI)· Source

• A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  NCT06542250· AstraZeneca· Source

• A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT05424822· Janssen Research & Development, LLC· Source

• Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

  NCT04419519· Memorial Sloan Kettering Cancer Center· Source

• Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

  NCT02296918· Acerta Pharma BV· Source

• Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

  NCT02290951· Regeneron Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 2
• Flow Cytometry 21
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 9
• Magnetic Resonance Imaging 4
• Machine Learning 10
• Cohort Studies 18
• Genome-Wide Association Study 2

• Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care.

  Support Care Cancer, Sept 2026

• Integrated analysis of IGHV rearrangements and cytogenetic abnormalities in a large chronic lymphocytic leukemia cohort (CLL-POL1).

  BMC Cancer, Jun 2026

• Pure Nodal Small Lymphocytic Lymphoma: Clinical, Pathologic, and Outcome Features in a Single-Center Cohort.

  Medicina (Kaunas), Jun 2026

• IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis.

  Ann Hematol, Jun 2026

• Risk of Skin Cancer Among Patients With Chronic Lymphocytic Leukemia.

  JAMA Dermatol, May 2026

• Real-World Treatment Patterns and Safety Outcomes of Targeted Therapies in a Single-Center Chronic Lymphocytic Leukemia Cohort.

  Medicina (Kaunas), Apr 2026

• Cardiovascular Disease Risk in Adults With Hematological Malignancies: A Population-Based Cohort Study Using Linked Databases.

  J Am Coll Cardiol, Apr 2026

• Pretreatment immunoglobulin profiles and survival outcomes in hematologic malignancies and autoimmune cytopenias: a comparative cohort analysis.

  BMC Immunol, Feb 2026

• Subsequent risk of non-keratinocyte skin cancers in adult cancer survivors: a SEER-based cohort study.

  BMJ Open, Jan 2026

• Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data.

  J Manag Care Spec Pharm, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.